(ENTX) Entera Bio Ltd. Business Model Canvas Research

Entera Bio Ltd. relies on manufacturing and formulation partners because oral large-molecule drugs need specialist drug substance, drug product, and stability work to support clinical supply. As a clinical-stage Company with no approved products, these partners are a core link in advancing assets like EB613 through development and batch release.

In 2025, the Company’s work stayed centered on clinical execution, so partner capacity and quality control directly affect trial timelines and supply continuity.

• Supports drug substance and drug product
• Runs stability testing for clinical lots
• Keeps trial supply moving

Entera Bio Ltd. relies on regulatory and IP counsel to guide trial filings, compliance, and patent coverage around its oral peptide and protein platform. That support helps protect proprietary know-how, lower filing risk, and preserve future licensing value.

• Trial filings and compliance support
• Patent protection for platform assets
• Stronger licensing leverage

Entera Bio Ltd. uses licensing and business development to widen its peptide platform beyond internal programs, including collaborative R&D and deals like its Amgen work. This matters because it can bring non-dilutive capital, lower R&D burn, and create a path to future commercialization without full internal buildout.

• Expands the platform beyond in-house programs
• Supports non-dilutive funding
• Builds future licensing revenue

Entera Bio Ltd. runs regulatory and quality operations to prepare clinical documents, file submissions, and keep trial materials and CMC readiness aligned with regulators. These controls help keep studies compliant and reduce delays in trial continuity.

• Clinical documents and submissions
• Quality systems for trial materials
• CMC readiness and compliance

Entera Bio Ltd.'s clinical data package is anchored by Phase I and Phase II readouts, and those results shape FDA talks, partner due diligence, and investor trust. For a small biotech, clean safety and efficacy data from 2 trial stages can matter more than pipeline size, because data quality often drives valuation, funding terms, and deal interest.

• Phase I and II results are core assets
• Support regulatory and partner talks
• Data quality can move valuation

Entera Bio Ltd. was founded in 2009 and is based in Jerusalem, Israel. Its key resources are IP, specialized scientific know-how, and a local team that supports R&D and oversight; as of its latest public filings, the company remains a clinical-stage biotech with no product revenue, so these assets are central to value creation.

• Founded: 2009
• HQ: Jerusalem, Israel
• Core assets: IP and scientific know-how
• Team supports research and oversight

One platform can feed multiple programs, so Entera Bio Ltd can spread R and D across two lead assets and a partnership-led discovery track. That gives the company more shot-on-goal for future indications without building a new tech stack each time.

• One platform, multiple programs
• Two lead assets in house
• Partnered discovery adds optionality

Entera Bio Ltd’s clinical-stage programs can draw larger pharma partners because human data reduces science risk versus preclinical assets. That matters for value: in 2025, Entera Bio Ltd had no product sales, so licensing, co-development, and milestone cash can be the main monetization path.

• Clinical data can support partnering talks
• Licensing can fund development without sales
• Milestones and royalties can extend value

Entera Bio Ltd.’s customer relationship with regulators is a formal, documentation-heavy one: every trial step depends on submissions, written feedback, and compliance checks that shape study design and timing. This matters most in a small biotech, where a single FDA/EMA decision can shift a development plan by quarters, not days.

• Submission-led, not sales-led
• Regulator feedback shapes trials
• Compliance drives timeline risk

Entera Bio Ltd. must share detailed technical and clinical know-how so partners can test the oral delivery platform and review pipeline assets faster; that knowledge transfer is central to moving from evaluation to new deals. It also helps support follow-on partnering talks, since collaborators need clear data on platform fit, development risk, and value.

• Share technical data early
• Support clinical review calls
• Speed partner due diligence
• Strengthen future deal talks

Scientific conferences and peer-reviewed publications help Entera Bio Ltd. build trust with clinicians and partners, because they show the oral peptide platform in public and support external validation. For a development-stage biotech with no approved products and no product revenue reported in its latest filings, this channel is key for scientific credibility and deal flow.

• Builds credibility with KOLs and investors
• Explains the oral delivery platform clearly
• Supports third-party validation and partnering

Entera Bio Ltd. uses IND and other clinical submissions as the gate to move a candidate from preclinical work into human testing; in the U.S., the FDA has 30 days to review an IND before trials can start. These filings must support Phase 1 through Phase 3 studies, so they create the formal path to later-stage development and, if successful, registration.

• IND starts human testing

• FDA review window: 30 days

• Needed for Phase 1-3 progression

Patients with non-healing bone fractures are a high-need niche for Entera Bio Ltd., because nonunion affects about 5% to 10% of fractures, and the global fracture burden is rising as osteoporosis cases grow. EB613 is in Phase I for this use, aiming at a clinically distinct group that often needs faster, more reliable bone-healing options.

• Phase I program: EB613
• Target: fracture nonunion patients
• High unmet need, distinct biology

Endocrinologists and orthopedic specialists are key adopters for Entera Bio Ltd., while hospitals and payers shape whether uptake scales. They are not the only buyers, but their buy-in drives prescribing, formulary access, reimbursement, and the path to future commercialization.

• Endocrinologists drive first use.
• Orthopedic specialists expand clinical reach.
• Hospitals control access.
• Payers decide reimbursement speed.

Entera Bio Ltd. keeps general and administrative overhead anchored in its Jerusalem HQ, where finance, legal, and corporate management add fixed costs. Public-company reporting under SEC and Nasdaq rules also lifts overhead, but these costs are needed to run the enterprise structure.

• Jerusalem HQ drives fixed overhead.
• Finance and legal stay core costs.
• Public reporting adds recurring expense.
• Supports corporate control and compliance.

Entera Bio Ltd. spends cash on regulatory filings, patent upkeep, and collaboration oversight, plus outside legal and consulting support. These fees protect the oral peptide platform and keep development moving, so they sit close to the core of the business model.

• Regulatory submissions
• Patent and IP defense
• Partner contract management
• External legal and consultant fees

Entera Bio Ltd. can use research collaboration funding as non-dilutive support, with partners helping pay for discovery and early development work instead of funding it only through equity raises. For a small biotech, that matters because it can stretch cash runway and reduce dilution pressure when R&D spend is still high.

• Partner-funded discovery work
• Less reliance on equity financing
• Supports early development

As of July 2026, Entera Bio Ltd. is still in clinical development, so it has no commercial product revenue from EB612 or EB613. In FY2025, revenue was not driven by marketed sales; any cash inflow is expected to come from partnerships, licensing, or collaboration milestones.

• No marketed product sales yet
• Revenue model stays partnership-led
• EB612 and EB613 remain clinical assets